Is T2 Biosystems still in business in 2026?

No. T2 Biosystems announced on February 3, 2026 its intent to complete winding down operations and voluntarily liquidate, after a failed 2025 sale process left it with extremely limited cash and significant liabilities. It has no employees, no officers besides a wind down administrator, and no revenue since February 2025.

Did T2 Biosystems get delisted from Nasdaq?

Yes. The Nasdaq Hearings Panel decided to delist T2 Biosystems common stock on February 10, 2025, with trading suspended February 12, 2025. Shares then moved to OTC markets under ticker TTOO, where by July 24, 2026 the market capitalization had fallen to roughly 0.006 million dollars.

Were there layoffs at T2 Biosystems?

Yes. On February 13, 2025 the board approved termination of substantially all employees. By April 4, 2025 all remaining officers and directors had also resigned, leaving Craig R. Jalbert, a distressed wind down specialist, as sole director, CEO, President, Treasurer and Secretary.

Who owns T2 Biosystems now?

T2 Biosystems remained a publicly traded company on OTC markets under ticker TTOO with diffuse shareholders and no parent company. As of the February 3, 2026 liquidation announcement, no acquirer had purchased the company or its assets, and its stock traded at fractions of a cent.

Could AI replace T2 Biosystems' diagnostic technology?

The question is largely moot since T2 Biosystems ceased operations in February 2025 and announced liquidation February 3, 2026. Its core T2MR whole blood detection was lab hardware, not AI displaceable, though competitors increasingly layer machine learning onto sequencing based pathogen identification.

Who is T2 Biosystems' biggest competitor?

Historic direct rivals in rapid bloodstream infection diagnostics included BioFire Diagnostics, a bioMerieux subsidiary, plus Cepheid under Danaher, Becton Dickinson, and Roche. As T2 exited the market via its February 2026 liquidation announcement, these incumbents retain the sepsis diagnostics market by default.

Biotech tools companies · absorbed · United States

T2 Biosystems, Inc.

t2biosystems.com ↗

Once-public maker of T2MR blood tests for sepsis and infection, now dissolving.

Little protection left

Assessed 24 July 2026 · Evidence as of 24 July 2026

Not much stands between this business and its pressures.

On the recordSince 24 July 2026 · Checkable from late 2026 · Every call on the record Checkpoint: Final SEC filings expected to close out reporting obligations as dissolution completes

The call

T2 Biosystems ran out of money and buyers, and is now closing down under a one-person administration with no equity value left.

T2 Biosystems made rapid blood tests to identify dangerous bacteria and fungi in hospitals. The company competed against much larger medical device makers like Danaher, Roche, and Becton Dickinson, which had more money, more customers, and established relationships with hospitals, making it very hard for T2 to gain ground. The company ran out of cash after attempting to find a buyer in 2025 and has now shut down completely, though its bacterial and fungal testing patents and FDA approvals may be purchased by another company during the liquidation process.

Why

AI pressure: None apparent. The company has no staff, no lab operations and no revenue left for any AI tool or rival to take. Could AI do the core job? Only partly.

Bigger players: bioMerieux (BioFire), Danaher (Cepheid), Becton Dickinson, Roche. These larger diagnostics makers already dominate sepsis testing; T2 Biosystems is closing from lack of cash, not a lost fight with them. Could a giant copy it? Yes, easily.

What protects it. None: all officers and directors resigned, staff were terminated, and the company is selling off assets to pay creditors.

What would change this call

Sale or license of T2MR patents and FDA 510(k) clearances during liquidation. Would show a buyer sees residual value in T2's sepsis diagnostic IP.
Formal SEC filings closing the company's reporting obligations. Would confirm T2 Biosystems has fully dissolved as a legal entity.
Announcement of a new entity built on T2's former T2Bacteria or T2Candida panels. Would show a successor is attempting to revive the underlying technology.

Key numbers

Announced intent to liquidate Feb 3, 2026 (2026-02-03)
Nasdaq delisting took effect Feb 10, 2025 (2025-02-10)
Board terminated nearly all staff Feb 13, 2025 (2025-02-13)

Named risks

Company has announced voluntary liquidation with no going concern as of February 3, 2026. Severity: high
Extremely limited cash and significant liabilities with secured debt unlikely to be satisfied. Severity: high
No employees, officers, or directors remain apart from a single wind down administrator since April 2025. Severity: high
Stock trading at fractions of a cent on OTC with market cap near zero as of July 24, 2026. Severity: medium
Failed 2025 sale process could not close a transaction satisfying secured debt or funding an asset sale. Severity: high

Rivals, as read in July 2026

Rival	Direction	Evidence
bioMerieux (BioFire Diagnostics)	gaining on	Retains full sepsis diagnostics market share by default after T2 Biosystems ceased operations February 2025 and announced liquidation February 3, 2026
Danaher (Cepheid)	gaining on	Named incumbent in molecular blood infection diagnostics as T2 Biosystems exits market entirely in 2026 liquidation
Becton Dickinson	gaining on	Cited as major sepsis diagnostics market share holder as of 2023 while T2 Biosystems wound down through 2025 to 2026
Roche	gaining on	Identified incumbent with major market share as T2 Biosystems ceased commercial activity after February 2025 shutdown

Questions people ask

Is T2 Biosystems still in business in 2026?: No. T2 Biosystems announced on February 3, 2026 its intent to complete winding down operations and voluntarily liquidate, after a failed 2025 sale process left it with extremely limited cash and significant liabilities. It has no employees, no officers besides a wind down administrator, and no revenue since February 2025.
Did T2 Biosystems get delisted from Nasdaq?: Yes. The Nasdaq Hearings Panel decided to delist T2 Biosystems common stock on February 10, 2025, with trading suspended February 12, 2025. Shares then moved to OTC markets under ticker TTOO, where by July 24, 2026 the market capitalization had fallen to roughly 0.006 million dollars.
Were there layoffs at T2 Biosystems?: Yes. On February 13, 2025 the board approved termination of substantially all employees. By April 4, 2025 all remaining officers and directors had also resigned, leaving Craig R. Jalbert, a distressed wind down specialist, as sole director, CEO, President, Treasurer and Secretary.
Who owns T2 Biosystems now?: T2 Biosystems remained a publicly traded company on OTC markets under ticker TTOO with diffuse shareholders and no parent company. As of the February 3, 2026 liquidation announcement, no acquirer had purchased the company or its assets, and its stock traded at fractions of a cent.
Could AI replace T2 Biosystems' diagnostic technology?: The question is largely moot since T2 Biosystems ceased operations in February 2025 and announced liquidation February 3, 2026. Its core T2MR whole blood detection was lab hardware, not AI displaceable, though competitors increasingly layer machine learning onto sequencing based pathogen identification.
Who is T2 Biosystems' biggest competitor?: Historic direct rivals in rapid bloodstream infection diagnostics included BioFire Diagnostics, a bioMerieux subsidiary, plus Cepheid under Danaher, Becton Dickinson, and Roche. As T2 exited the market via its February 2026 liquidation announcement, these incumbents retain the sepsis diagnostics market by default.

Timeline

2026-02-03T2 Biosystems announces intent to complete winding down operations and voluntarily liquidate
2025-04-04All remaining officers and directors resign; Craig R. Jalbert becomes sole director, CEO, President
2025-02-13Board approves termination of substantially all employees
2025-02-12Trading of TTOO common stock suspended, later moves to OTC markets
2025-02-10Nasdaq Hearings Panel determines to delist T2 Biosystems common stock
2025-02-01Company engages investment bank specializing in distressed biotech to pursue sale
2024-05-21Company regains Nasdaq continued listing compliance after temporary exception
2023-11-30Nasdaq notifies company it failed the 35 million dollar market value of listed securities requirement
2023-10-31Company executes 1 for 100 reverse stock split
2014-08-06T2 Biosystems IPOs, raising 83 million dollars at 15 to 17 dollars per share

Revision history

24 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

Singular Genomics Synthego Corporation Standard BioTools